Gilead Sciences Company Profile (NASDAQ:GILD)

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences declared a quarterly dividend on Tuesday, May 2nd. Investors of record on Friday, June 16th will be given a dividend of $0.52 per share on Thursday, June 29th. This represents a $2.08 annualized dividend and a yield of 2.82%. The ex-dividend date of this dividend is Wednesday, June 14th. View Gilead Sciences' Dividend History.

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings results on Tuesday, May, 2nd. The company reported $2.20 EPS for the quarter, topping the Zacks' consensus estimate of $2.18 by $0.02. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.66 billion. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. View Gilead Sciences' Earnings History.

26 brokers have issued twelve-month price targets for Gilead Sciences' shares. Their predictions range from $65.50 to $95.00. On average, they anticipate Gilead Sciences' share price to reach $80.32 in the next twelve months. View Analyst Ratings for Gilead Sciences.

Here are some recent quotes from research analysts about Gilead Sciences stock:

• 1. According to Zacks Investment Research, "Gilead’s HIV franchise has been gaining momentum of late. Rapid adoption of TAF-based regimens, representing 42% of total Gilead HIV prescription volume, following the launch of Genvoya and the launches of Odefsey and Descovy in 2016 boosted results. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales.The company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. The company submitted a NDA to the FDA for single tablet regimen for bictegravir. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. In addition, the HCV franchise continues to be under competitive and pricing pressure leading to a decline in Harvoni and Sovaldi sales." (7/18/2017)
• 2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
• 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
• 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)

Gilead Sciences saw a increase in short interest in the month of June. As of June 30th, there was short interest totalling 13,658,785 shares, an increase of 15.7% from the June 15th total of 11,804,652 shares. Based on an average trading volume of 13,707,757 shares, the short-interest ratio is currently 1.0 days. Currently, 1.1% of the company's shares are short sold.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Celgene Corporation (CELG), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), bluebird bio (BLUE), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), BeiGene (BGNE), GW Pharmaceuticals PLC (GWPH), Agios Pharmaceuticals (AGIO) and China Biologic Products (CBPO).

Gilead Sciences' management team includes the folowing people:

• John C. Martin Ph.D., Executive Chairman of the Board
• John F. Milligan Ph.D., Chief Executive Officer, Director
• Robin L. Washington, Chief Financial Officer, Executive Vice President
• Kevin B. Young, Chief Operating Officer
• Norbert W. Bischofberger Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
• Gregg H. Alton, Executive Vice President - Corporate and Medical Affairs
• James R. Meyers, Executive Vice President - Worldwide Commercial Operations
• John F. Cogan Jr. Ph.D., Lead Independent Director
• Kelly A. Kramer, Independent Director
• Kevin E. Lofton, Independent Director

Gilead Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include APG Asset Management N.V. (0.42%), State Treasurer State of Michigan (0.24%), Swedbank (0.17%), PGGM Investments (0.11%), AMF Pensionsforsakring AB (0.09%) and Chevy Chase Trust Holdings Inc. (0.09%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., NN Investment Partners Holdings N.V., First Quadrant L P CA, Boston Advisors LLC, Parkwood LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Russell Investments Group Ltd. and Beech Hill Advisors Inc.. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton and Paul Rutherford Carter. View Insider Buying and Selling for Gilead Sciences.

Gilead Sciences' stock was purchased by a variety of institutional investors in the last quarter, including ANTIPODES PARTNERS Ltd, Aperio Group LLC, Foundation Resource Management Inc., Manning & Napier Advisors LLC, Mn Services Vermogensbeheer B.V., US Bancorp DE, National Pension Service and Exane Asset Management. View Insider Buying and Selling for Gilead Sciences.

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Gilead Sciences stock can currently be purchased for approximately $73.74.